Ionis Pharmaceuticals announces Phase 3 CORE, CORE2 met primary endpoint

Ionis Pharmaceuticals (IONS) announced positive results from the Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia, sHTG. The studies met the primary endpoint, with olezarsen achieving a highly statistically significant placebo-adjusted mean reduction in fasting triglyceride levels of up to 72% at six months. The reductions were sustained through 12 months. Olezarsen showed a highly statistically significant 85% reduction in acute pancreatitis events, the first and only time achieved in sHTG. Additionally, 86% of olezarsen-treated patients achieved triglyceride levels less than 500 mg/dL, below the risk threshold for acute pancreatitis. Olezarsen demonstrated favorable safety and tolerability.